Summit Trail Advisors’s Charles River Laboratories CRL Stock Holding History

Summit Trail Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.95M	Sell	13,010 -3,552	-21%	-$633K	0.04%	375
2026 Q1	$2.86M	Sell	16,562 -547	-3%	-$101K	0.04%	328
2025 Q4	$3.41M	Sell	17,109 -1,441	-8%	-$261K	0.06%	196
2025 Q3	$2.9M	Buy	18,550 +4,107	+28%	+$652K	0.04%	258
2025 Q2	$2.19M	Buy	+14,443	New	+$1.93M	0.04%	246
2018 Q1	–	Sell	-125	Closed	-$13K	–	703
2017 Q4	$13K	Buy	+125	New	+$13.6K	﹤0.01%	1150

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Summit Trail Advisors's CRL Position: Q2 2026 in Review

Summit Trail Advisors reduced its Charles River Laboratories (CRL) stake by 21% in Q2 2026, selling an estimated $633K and leaving 13,010 shares worth $2.95M. The position accounts for 0.04% of the portfolio, ranked #375.

Summit Trail Advisors first reported a position in CRL in Q4 2017 and has held it in 6 quarters since. The position peaked at $3.41M in Q4 2025. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Summit Trail Advisors held 13,010 shares of Charles River Laboratories worth $2.95M as of Q2 2026.
Summit Trail Advisors sold 3,552 Charles River Laboratories shares in Q2 2026, an estimated $633K.
Charles River Laboratories made up 0.04% of Summit Trail Advisors's portfolio in Q2 2026, its #375 holding.
Summit Trail Advisors first reported a position in Charles River Laboratories in Q4 2017 and has held it in 6 quarters since.
Summit Trail Advisors's Charles River Laboratories position peaked at $3.41M in Q4 2025.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.